Happy New Year from the Coulter Partners team!

Happy New Year from the Coulter Partners team!

We finished 2025 strong, kicking off some exciting projects and feeling real momentum across life sciences and healthtech. The mood heading into JPM is positive after a productive Jefferies event, and people are genuinely excited about the year ahead.

Looking at 2026, the consensus is clear. It is a cautious rebound where quality science and strong leadership matter most. We expect to see more M&A and partnerships as pharma works to fill pipeline gaps, and capital is flowing into the best opportunities. AI is moving from pilot programs to part of the operating model, which means execution and talent are more important than ever.

Here’s to a year of progress, innovation, and impact.